Validation of patient-reported outcome measures for dactylitis, psoriatic skin and nail disease, and uveitis in patients with psoriatic arthritis in routine care

Competing Interest Statement

LMN: Grants or contracts from any entity: The Danish Rheumatism Association (paid to institution) LD: Grants or contracts from any entity: Contract with BMS and AbbVie outside the present work (paid to institution) Support for attending meetings and/or travel: Janssen, UCB, Boehringer Ingelheim Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Chair of the scientific committee of the Danish Rheumatism Association (unpaid) and member of DANBIOS steering committee (unpaid) LS: Grants or contracts from any entity: Almirall, Janssen, Bristol-Myers Squibb, UCB, and Sanofi (paid to institution) Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: BMS, LEO Pharma, Pfizer, Janssen, AbbVie, Takeda and Sanofi (payment to LS) Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie, Novartis, Almirall, LEO Pharma, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, UCB, Eli Lilly, Stada, Takeda and Sanofi (payment to LS) Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: IPC, board member (unpaid) MLH: Grants or contracts from any entity: AbbVie, AlfaSigma, BMS, Eli Lilly, MSD, Pfizer, Sandoz, Novartis, Nordforsk, UCB (paid to my institution) Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pfizer, Medac, Sandoz, UCB (paid to institution) Novartis (paid to institution and to MH) Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie (paid to institution) Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: MLH has chaired the steering committee of the Danish Rheumatology Quality Registry (DANBIO, DRQ), which receives public funding from the hospital owners and funding from pharmaceutical companies. MLH co-chairs EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondylarthritis based on secondary data and is partly funded by Novartis and UCB. BG: Grants or contracts from any entity: Pfizer, AbbVie, Sandoz, Eli Lilly, AlfaSigma (paid to institution) Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Chair of the DANBIO steering Commitee

Funding Statement

This study was funded by The Danish Rheumatism Association

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Scientific Ethical Committees of the Capital Region of Denmark waived ethical approval for this work File number: F-23061081

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes